Sight Sciences Files 10-Q: Financials and Operations Update

TL;DR

Sight Sciences 10-Q is in! Check Q2 financials, surgical glaucoma progress, and Hercules credit details.

AI Summary

Sight Sciences, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates, including information related to their surgical glaucoma products and the Hercules Credit Agreement. Specific financial figures and operational metrics for the quarter and year-to-date are presented.

Why It Matters

This filing provides investors and stakeholders with a crucial update on Sight Sciences' financial health and strategic direction, impacting investment decisions and market perception.

Risk Assessment

Risk Level: medium — The filing contains financial data and operational details that could influence stock price, but doesn't indicate immediate severe risks.

Key Numbers

• Q2 2024 — Reporting Period (Financial and operational data for the second quarter of 2024.)
• 2024-06-30 — Balance Sheet Date (The date as of which the company's financial position is reported.)
• 2023-12-31 — Prior Year End (Comparison point for financial performance.)

Key Players & Entities

• Sight Sciences, Inc. (company) — Filer of the 10-Q
• Hercules Credit Agreement (company) — Financial agreement mentioned
• Surgical Glaucoma (company) — Product category
• 2024-06-30 (date) — End of reporting period

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SGHT The Nasdaq Global Se

Filing Documents

• sght-20240630.htm (10-Q) — 1737KB
• sght-ex31_1.htm (EX-31.1) — 21KB
• sght-ex31_2.htm (EX-31.2) — 20KB
• sght-ex32_1.htm (EX-32.1) — 10KB
• sght-ex32_2.htm (EX-32.2) — 10KB
• 0000950170-24-090008.txt ( ) — 7647KB
• sght-20240630.xsd (EX-101.SCH) — 1308KB
• sght-20240630_htm.xml (XML) — 1259KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32 PART II. OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

Signatures

Signatures 36 2 SPECIA L NOTE REGARDING FORWARD-LOOKING STATEMENTS Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to the "Company," "Sight Sciences," "we," "us" and "our" refer to Sight Sciences, Inc. This Quarterly Report on Form 10-Q for the fiscal period ended June 30, 2024 (this "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "hope," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: our ability to obtain and maintain sufficient reimbursement for our products, including our ability to maintain competitive reimbursement for our Surgical Glaucoma products and establish sufficient reimbursement for our Dry Eye products; our ability to compete effectively with existing competitors and new market entrants; estimates of our total addressable market, revenue, expenses, liquidity, capital requirements, and needs for additional fi

Financial Statements

Item 1. Financial Statements SIGHT SCIENCES, INC. Condensed Consolidated Balan ce Sheets (Unaudited) (in thousands, except share and per share data) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 118,177 $ 138,129 Accounts receivable, net of allowance for credit losses of $ 1,059 and $ 1,186 at June 30, 2024 and December 31, 2023, respectively 19,919 14,289 Inventory, net 6,781 7,849 Prepaid expenses and other current assets 1,452 2,604 Total current assets 146,329 162,871 Property and equipment, net 1,489 1,640 Operating lease right-of-use assets 1,257 1,458 Other noncurrent assets 640 682 Total assets $ 149,715 $ 166,651 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,923 $ 1,731 Accrued compensation 5,394 4,528 Accrued and other current liabilities 5,971 3,774 Current portion - long-term debt, net — 2,219 Total current liabilities 13,288 12,252 Long-term debt, net 33,770 31,708 Other noncurrent liabilities 1,019 2,476 Total liabilities 48,077 46,436 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 — — Common stock, par value $ 0.001 per share; 200,000,000 shares authorized; 50,136,131 and 49,131,363 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 50 49 Additional paid-in-capital 424,973 414,956 Accumulated deficit ( 323,385 ) ( 294,790 ) Total stockholders' equity 101,638 120,215 Total liabilities and stockholders' equity $ 149,715 $ 166,651 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 SIGHT SCIENCES, INC. Condensed Consoli dated Statements of Operations and

View Full Filing

View this 10-Q filing on SEC EDGAR